Sangamo BioSciences | SGMO - Equity Capital And Reserves


Sangamo BioSciences reported $19.6M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Amgen USD 9.19B 532M Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cipla INR 344.32B 15.13B Mar/2026
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 95.35M 7.38M Mar/2026
CSL USD 18.66B 2.75B Dec/2025
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
J&J USD 81.19B 358M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Pfizer USD 90.1B 3.63B Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026